AKT1 and thyroid cancer: Hou et al. (65) validated the impact of various inhibitors – RDEA119 (MAPK inhibitor), temsirolimus (mTOR inhibitor), perifosine (AKT inhibitor) and SAHA (HDACI) – on iodine-handling gene expression and RAI uptake in thyroid cancer cell lines.